CClinicalTrials.gg
Enrolling by invitationNCT06566053Updated Aug 22, 2024

Establishment of a Predictive System for Perioperative Risk Assessment and Electronic Flowcharting Response Strategies in Thoracic Surgery

An observational study in Perioperative Complications, sponsored by Hengxing Liang. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by Hengxing Liang · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Study summary

  1. To establish a risk assessment scale for thoracic surgery for the Chinese population, and to classify patients; risk according to the relevant scale;
  2. Combining the guidelines for the management of acute and critical illnesses in thoracic surgical care units and the characteristics of diagnosis and treatment operations, to make an AI-assisted diagnosis and treatment process software;
  3. Evaluate whether the software can provide timely and correct diagnosis and treatment recommendations for critically ill patients, shorten the time for homogenized training of specialist intensivists, and reduce the hospitalization cost of patients under the review of resident training instructors of various specialties.
02

Conditions studied

  • Perioperative Complications
03

In context

Lead sponsor

This is the only study on the registry with Hengxing Liang as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to the Department of Thoracic Surgery of the Second Xiangya Hospital of Central South University for surgical treatment.

Inclusion criteria

  • Patients admitted to the Department of Thoracic Surgery of the Second Xiangya Hospital of Central South University for surgical treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients admitted to the Department of Thoracic Surgery of the Second Xiangya Hospital of Central South University without surgical treatment.

Patients under the age of 18.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients who underwent thoracic surgery

    Gender:Both Participant age:18-100 Examples include early-stage non-small cell lung cancer (NSCLC), NSCLC patients who have undergone neoadjuvant therapy, esophageal diseases, mediastinal masses, chest wall disorders, and other related conditions.

    Other: Observation

Interventions

  • OtherObservation

    Observation

06

What researchers measure

Primary outcomes

  1. Acute Respiratory Distress Syndrome

    ARDS definition was based on the new global definition of ARDS10. Briefly, intubated ARDS was defined as an oxygenation index of less than 300 under a positive end-expiratory pressure (PEEP) of at least 5 cmH2O, and non-intubated ARDS was defined as patients receiving high-flow nasal oxygen (HFNO) ≥ 30 L/min or noninvasive ventilation/continuous positive airway pressure (NIV/CPAP) with a PEEP of at least 5 cmH2O and meeting PaO2:FiO2 ≤ 300 mm Hg or SpO2:FiO2 ≤ 315 (if SpO2 ≤ 97%).

    Time frame: 2024.8-2024.12

Secondary outcomes

  1. In hospital mortality

    refers to the number or percentage of patients who die while being treated in a hospital.

    Time frame: 2024.8-2024.12

  2. Length of hospital stay

    Length of hospital stay(days): refers to the total number of days a patient spends in the hospital from the time of admission to the time of discharge.

    Time frame: 2024.8-2024.12

  3. Length of ICU stay

    Length of ICU stay(hours): refers to the total duration of time a patient spends in the Intensive Care Unit (ICU) during a single admission.

    Time frame: 2024.8-2024.12

  4. Length of postoperative stay

    Length of postoperative stay(days): refers to the duration of time a patient remains in the hospital or medical facility after undergoing surgery.

    Time frame: 2024.8-2024.12

  5. Duration of mechanical ventilation

    Duration of mechanical ventilation(hours): refers to the length of time a patient requires assistance from a mechanical ventilator to maintain adequate breathing.

    Time frame: 2024.8-2024.12

  6. Duration of HFNC

    Duration of HFNC(hours): refers to the length of time that a patient is treated with High-Flow Nasal Cannula (HFNC) therapy.

    Time frame: 2024.8-2024.12

07

Study locations

1 site
  • the Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06566053
Lead sponsor
Hengxing Liang
Collaborators
Changsha Xinghong Network Technology Co.
Responsible party
Hengxing Liang (Associate professor, Central South University) — Sponsor-investigator
First posted
Aug 22, 2024
Start date
Jul 1, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Aug 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion